Pemetrexed for the treatment of malignant pleural mesothelioma

NICE technology appraisals [TA135] Published date:

Pemetrexed is recommended as a possible treatment for malignant pleural mesothelioma in people:

  • with advanced disease
  • whose cancer is not suitable for surgical resection (removal) and
  • who have a World Health Organization (WHO) performance status of 0 (able to carry out all normal activity without restriction) or 1 (restricted in strenuous activity but able to move around and carry out light work).

Healthcare professionals should not stop prescribing pemetrexed for people who were already taking it when the guidance was issued. These patients should be able to carry on taking pemetrexed until they and their specialist decide that it is the right time to stop treatment.

Get involved